Anti-LAGE-1 antibody [EPR12527]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(2 Publications)
Rabbit Recombinant Monoclonal LAGE-1 antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications.
View Alternative Names
ESO2, LAGE1, CTAG2, Cancer/testis antigen 2, CT2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1, CT6.2, LAGE-1
- WB
Supplier Data
Western blot - Anti-LAGE-1 antibody [EPR12527] (AB177947)
All lanes:
Western blot - Anti-LAGE-1 antibody [EPR12527] (ab177947) at 1/1000 dilution
Lane 1:
Human melanoma lysate at 10 µg
Lane 2:
Human prostate cancer lysate at 10 µg
Predicted band size: 21 kDa
false
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purity
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
LAGE-1 functions as part of a mechanism contributing to tumor immunogenicity. It participates in the presentation of peptides on the surface of cancer cells facilitating their recognition by T cells and subsequent immune targeting. LAGE-1 does not operate in isolation but may interact within a larger complex of similar antigens enhancing the immune system's ability to identify and combat malignancies.
Pathways
The involvement of LAGE-1 in immune surveillance pathways is essential. It interacts with components of the major histocompatibility complex (MHC) class I antigen presentation pathway. By associating with proteins involved in this pathway LAGE-1 enhances the visibility of cancer cells to cytotoxic T lymphocytes. Other proteins such as LAGE-1's homolog MAGE-A share similar pathways suggesting overlapping roles in the formation of antigen complexes and subsequent immune recognition.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (2)
Recent publications for all applications. Explore the full list and refine your search
Nature communications 15:5237 PubMed38898005
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal of translational medicine 20:255 PubMed35668458
2022
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com